| NCT06387121 | Institute of Hematology & Blood Diseases Hospital, China | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2024-04-02 | PHASE2 |
| NCT05597085 | Pfizer | Adult Relapsed+Refractory B Cell Acute Lymphoblastic Leukemia | 2023-03-08 | |
| NCT06287229 | M.D. Anderson Cancer Center | Relapsed+Refractory|B-cell Acute Lymphocytic Leukemia | 2024-07-11 | PHASE1|PHASE2 |
| NCT00867087 | Pfizer|UCB Pharma | Lymphoma, B-Cell | 2009-06-08 | PHASE2 |
| NCT06863259 | Children´s Hospital Medical Center, Cincinnati | B-cell Acute Lymphoblastic Leukemia | 2025-05-21 | PHASE1 |
| NCT06087419 | Institute of Hematology & Blood Diseases Hospital, China | Acute Lymphoblastic Leukemia | 2023-10-30 | PHASE1|PHASE2 |
| NCT03677596 | Pfizer | Leukemia|Precursor b-Cell Lymphoblastic Leukemia-Lymphoma|ACUTE LYMPHOBLASTIC LEUKEMIA | 2019-07-01 | PHASE4 |
| NCT06554626 | First Affiliated Hospital of Zhejiang University | Precursor B-Cell Lymphoblastic Leukemia | 2024-08-15 | PHASE2 |
| NCT01664910 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Hematopoietic and Lymphoid Cell Neoplasm | 2012-10-29 | PHASE1|PHASE2 |
| NCT03851081 | Roswell Park Cancer Institute|Pfizer | Allogeneic Hematopoietic Stem Cell Transplantation Recipient|Blasts 5 Percent or More of Bone Marrow Nucleated Cells|Blasts 5 Percent or More of Peripheral Blood White Cells|CD22 Positive|Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells|Lymphoblasts 20 Percent or More of Peripheral Blood White Cells|Recurrent B Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia | 2021-01-21 | PHASE1|PHASE2 |
| NCT03249870 | Versailles Hospital | Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22&addition; B-cell Precursor (BCP) | 2017-12-28 | PHASE2 |
| NCT00562965 | Pfizer|UCB Pharma | Lymphoma, Follicular | 2007-11 | PHASE3 |
| NCT06533748 | St. Jude Children´s Research Hospital|Pfizer|Amgen | Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma | 2025-01-23 | PHASE2 |
| NCT05748171 | Pfizer | ACUTE LYMPHOBLASTIC LEUKEMIA | 2023-05-17 | PHASE2 |
| NCT01925131 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Acute Leukemias of Ambiguous Lineage|B-cell Adult Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma | 2014-06-13 | PHASE1 |
| NCT03488225 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Acute Lymphoblastic Leukemia in Remission|B Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 2018-03-28 | PHASE2 |
| NCT05016947 | Dana-Farber Cancer Institute|AbbVie | B-cell Acute Lymphoblastic Leukemia|B-Cell Lymphoma|ALL | 2021-09-24 | PHASE1 |
| NCT00724971 | Pfizer | Lymphoma, B-Cell | 2008-07-04 | PHASE1 |
| NCT01363297 | Pfizer|UCB Pharma | Acute Lymphocytic Leukemia | 2011-08 | PHASE2 |
| NCT03094611 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | CD22 Positive|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia | 2017-11-30 | PHASE2 |
| NCT05603156 | Institute of Hematology & Blood Diseases Hospital, China | Ph&addition; ALL|Bone Marrow Transplant|Minimal Residual Disease | 2022-10-30 | NA |
| NCT03104491 | Leland Metheny | Acute Lymphocytic Leukemia | 2017-07-31 | PHASE1|PHASE2 |
| NCT05303792 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma | 2023-06-09 | PHASE2 |
| NCT04747912 | University of Chicago | Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia|ph&addition; Acute Lymphoblastic Leukemia | 2021-03-02 | PHASE2 |
| NCT02311998 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|CD22 Positive|Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | 2015-04-16 | PHASE1|PHASE2 |
| NCT07238907 | Ruijin Hospital | Acute Lymphoblastic Leukaemia|Acute Lymphoblastic Leukaemias (ALL)|Inotuzumab Ozogamicin|Venetoclax | 2022-06-01 | |
| NCT04307576 | Mats Heyman|The Swedish Research Council|The Swedish Childhood Cancer Foundation|Pfizer|Servier|NordForsk|Aamu Pediatric Cancer Foundation|German Society for Pediatric Oncology and Hematology GPOH gGmbH|Clinical Trial Center North (CTC North GmbH & Co. KG)|Belgium Health Care Knowledge Centre|Karolinska Institutet|Cancer Research UK|Funda??o Rui Osório de Castro|Acreditar - Associa??o de Pais e Amigos das Crian?as com Cancro|Grupo Português De Leucemias Pediátricas|Amgen|Nova Laboratories Limited|Danish Child Cancer Foundation|Danish Cancer Society|The Novo Nordic Foundation|Assistance Publique - H?pitaux de Paris|Direction Générale de l´Offre de Soins|Swedish Cancer Society | Leukemia, Acute Lymphoblastic | 2020-07-13 | PHASE3 |
| NCT01055496 | Pfizer|UCB Pharma | Lymphoma, B-Cell | 2010-03 | PHASE1 |
| NCT06427330 | Institute of Hematology & Blood Diseases Hospital, China | Acute Lymphoid Leukemia | 2024-07-02 | PHASE2 |
| NCT06861348 | First Affiliated Hospital of Zhejiang University | Leukemia, Lymphocytic, Acute | 2025-03-01 | PHASE2 |
| NCT03610438 | Gruppo Italiano Malattie EMatologiche dell´Adulto | Acute Lymphoid Leukemia | 2019-10-30 | PHASE2 |
| NCT05456698 | Institute of Hematology & Blood Diseases Hospital, China | Acute Lymphocytic Leukemia | 2022-10-18 | PHASE2 |
| NCT00073749 | Pfizer | Lymphoma, B-Cell | 2003-08 | PHASE1 |
| NCT05940961 | Sheng-Li Xue, MD|Jining Medical University|The Second People´s Hospital of Huai´an|The First Affiliated Hospital of Bengbu Medical University|Affiliated Hospital of Nantong University|Suzhou Hospital of Traditional Chinese Medicine|Northern Jiangsu People´s Hospital | ALL|MRD-positive|Hematopoietic Stem Cell Transplantation | 2022-08-01 | PHASE2 |
| NCT00717925 | Wyeth is now a wholly owned subsidiary of Pfizer | Lymphoma, B-Cell | 2007-03 | PHASE1 |
| NCT03856216 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia|Lymphocytic Neoplasm|Lymphoma | 2019-10-28 | PHASE2 |
| NCT03739814 | National Cancer Institute (NCI) | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative|Recurrent B Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia | 2019-05-08 | PHASE2 |
| NCT03962465 | University of Virginia|Pfizer|Vanderbilt University|University of Wisconsin, Madison|Virginia Commonwealth University | B-cell Acute Lymphoblastic Leukemia | 2022-07-22 | PHASE1 |
| NCT07476729 | Charite University, Berlin, Germany | B-Cell Acute Lymphoblastic Leukaemia | 2026-04-01 | PHASE3 |
| NCT00868608 | Pfizer|UCB Pharma | Lymphoma | 2009-07-30 | PHASE2 |
| NCT03460522 | Nicola Goekbuget | Precursor Cell Lymphoblastic Leukemia | 2018-05-02 | PHASE2 |
| NCT05687032 | Pfizer | Acute Lymphoblastic Leukemia | 2023-02-24 | PHASE4 |
| NCT00299494 | Pfizer|UCB Pharma | B-Cell Lymphoma | 2006-05-04 | PHASE1|PHASE2 |
| NCT04456959 | Pfizer | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2020-01-06 | |
| NCT03441061 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia|Recurrent B Acute Lymphoblastic Leukemia | 2018-02-15 | PHASE2 |
| NCT03127605 | Pfizer | | | |
| NCT01564784 | Pfizer|UCB Pharma | Acute Lymphoblastic Leukemia | 2012-08-02 | PHASE3 |
| NCT04307134 | Pfizer | Hematologic Malignancy | 2020-07-09 | |
| NCT03991884 | University of Washington|Pfizer | Recurrent B Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory B Lymphoblastic Lymphoma | 2019-09-24 | PHASE1 |
| NCT02981628 | Children´s Oncology Group|National Cancer Institute (NCI) | Recurrent B Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory B Lymphoblastic Lymphoma | 2017-06-19 | PHASE2 |
| NCT01232556 | Pfizer|UCB Pharma | Lymphoma, Non-Hodgkin | 2011-04-04 | PHASE3 |
| NCT06985485 | The First Affiliated Hospital of Soochow University | Acute Lymphoblastic Leukemia|Immunotherapy|Blinatumomab|Inotuzumab Ozogamicin | 2025-05-17 | PHASE2 |
| NCT03913559 | St. Jude Children´s Research Hospital|Pfizer | Acute Lymphoblastic Leukemia | 2019-05-14 | PHASE2 |
| NCT05645718 | M.D. Anderson Cancer Center | Leukemia | 2023-07-14 | PHASE2 |
| NCT03959085 | Children´s Oncology Group|National Cancer Institute (NCI) | B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Central Nervous System Leukemia|Mixed Phenotype Acute Leukemia|Testicular Leukemia | 2019-10-31 | PHASE3 |
| NCT01371630 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative|Burkitt-Like Lymphoma With 11q Aberration|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Burkitt Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory Burkitt Lymphoma | 2011-08-26 | PHASE1|PHASE2 |
| NCT01679119 | University College, London|Pfizer|Cancer Research UK | Diffuse Large B Cell Lymphoma | 2013-10 | PHASE2 |
| NCT03150693 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | B Acute Lymphoblastic Leukemia | 2017-09-20 | PHASE3 |